Clinical Trials
18
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (18 trials with phase data)• Click on a phase to view related trials
PM8002 (BNT327) in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
- Conditions
- CRC (Colorectal Cancer)
- Interventions
- First Posted Date
- 2025-08-21
- Last Posted Date
- 2025-08-21
- Lead Sponsor
- Biotheus Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT07133750
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer
- First Posted Date
- 2024-09-27
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Biotheus Inc.
- Target Recruit Count
- 404
- Registration Number
- NCT06616532
- Locations
- 🇨🇳
Jilin Provincial Tumor Hospital, Changchun, China
🇨🇳Affiliated Hospital of Nantong University, Nantong, Jiangsu, China
🇨🇳The First Affiliated Hospital Of Ningbo University, Ningbo, Zhejiang, China
A Clinical Trial to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCC
- Conditions
- HCCLiver Cancer
- Interventions
- First Posted Date
- 2024-09-04
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Biotheus Inc.
- Target Recruit Count
- 140
- Registration Number
- NCT06584071
PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC
- Conditions
- Triple Negative Breast Cancer(TNBC)
- Interventions
- First Posted Date
- 2024-05-17
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- Biotheus Inc.
- Target Recruit Count
- 360
- Registration Number
- NCT06419621
- Locations
- 🇨🇳
The first affiliated hospital of bengbu medical University, Bengbu, Anhui, China
🇨🇳The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
A Study of PM1015 in Patients With Advanced Solid Tumors
- Conditions
- Advanced Solid Tumor
- Interventions
- Drug: CD73 Antigen
- First Posted Date
- 2023-07-18
- Last Posted Date
- 2023-07-18
- Lead Sponsor
- Biotheus Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT05950815
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, China
- Prev
- 1
- 2
- 3
- 4
- Next
News
BioNTech's VEGF x PD-L1 Bispecific BNT327 Shows Promise in TNBC
BioNTech's BNT327, a VEGF x PD-L1 bispecific antibody, demonstrates encouraging Phase II survival data in triple-negative breast cancer (TNBC).